PFE - Pfizer Inc.
| Previous Close | 36.42 |
| Open | 36.30 |
| Bid | 36.02 x 1300 |
| Ask | 36.64 x 900 |
| Day's Range | 36.30 - 36.78 |
| 52 Week Range | 29.83 - 36.78 |
| Volume | 15,159,383 |
| Avg. Volume | 17,130,350 |
| Market Cap | 216.48B |
| Beta | 1.09 |
| PE Ratio (TTM) | 26.63 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (3.51%) |
| Ex-Dividend Date | 2017-11-09 |
| 1y Target Est | N/A |
Markit•22 hours agoSee what the IHS Markit Score report has to say about Pfizer Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $183 million.
- Zacks•4 days ago
Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
- Motley Fool•4 days ago
3 High-Yield Pharmaceutical Stocks
High-yield pharma stocks are rare, but these three offer comparatively fat payouts.
- Market Realist•4 days ago
What’s Driving Economic Moats
"How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.
- Zacks•5 days ago
Healthcare ETFs Head to Head: XLV vs. VHT
Head to head comparison of two Healthcare ETFs, XLV and VHT.
- InvestorPlace•5 days ago
3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.
- Zacks•5 days ago
Conatus Entrusts Keith W. Marshall With Key Management Roles
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
- Barrons.com•5 days ago
4 Cheap Stock Picks for the Impatient
General Motors stock has a rare combination of a breakdown valuation and zippy price momentum. That is, it trades at eight times forward earnings estimates, making it less than half as expensive as the ...
- Market Realist•5 days ago
Inside Pfizer’s Performance in 3Q17
PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.
- Motley Fool•5 days ago
2 Great Stocks For Retirees
Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.
- Motley Fool•5 days ago
3 High-Yield Stocks for Conservative Investors
These solid businesses with great dividend yields hit the sweet spot for conservative investors.
- The Wall Street Journal•5 days ago
[$$] Reckitt Makeover Clears Way for Pfizer Bid
The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.
- Zacks•6 days ago
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
- Motley Fool•6 days ago
Here's Why Ignyta Stock Soared as Much as 27.5% Today
The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.
InvestorPlace•6 days agoDow Jones Industrial Average Hits 23,000. Now What?
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue?
Reuters•6 days agoReckitt to reshape as sales growth evaporates
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.
- Financial Times•6 days ago
[$$] Reckitt Benckiser: fission for compliments
In the physics of business, the entropic forces that break down a system can also liberate energy. Hidden value is meant to be released from spin-offs and the like, especially when profit growth slows. ...
- Reuters•6 days ago
Reckitt to reshape as sales growth evaporates
Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...
- Bloomberg•6 days ago
Pfizer's Advil May Be Just the Thing for Sickly Reckitt
The problem is getting shareholders to back a cash call to pay for it.
- Reuters•6 days ago
Reckitt Benckiser to form two business units for better focus
Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.
- Bloomberg•6 days ago
Reckitt CEO Focuses on Health, Looking Beyond Worst Year
Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....
- Forbes•6 days ago
Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.
Yahoo Finance Video•5 days agoThere's no reason for investors to sell stocks now: NYSE trader
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.
Yahoo Finance Video•5 days agoBuyers never came in that Monday in '87—it was chaos: NYSE trader
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the New York Stock Exchange to discuss his firsthand account of what it was like on the floor that day.
Yahoo Finance Video•5 days agoI'm bullish on American Express and Verizon: NYSE trader
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest Q3 earnings. Disclosure: Verizon is Yahoo Finance's parent company, and Alan Valdes owns shares of the company.
